- Cryoport looks well-positioned to benefit from macroeconomic crosscurrents that are driving value in biological logistics.
- The company is now supporting 69 Phase 3 clinical trials, evidencing a tide of regulatory momentum yet to be priced in.
- We see a fair value of $96 across a range of robust valuation measures, which implies respectable upside potential.
- Downside risks appear to be a slight disconnect from CYRX's share price and its top-line fundamentals.
- Here we cover all of the moving parts in the investment debate for the benefit of investors' own reasoning.
For further details see:
Cryoport: Unfairly Punished, Valuation Update Shows 45% Upside